Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Non-Current Deffered Revenue: 2018-2024

Historic Non-Current Deffered Revenue for Dianthus Therapeutics (DNTH) over the last 5 years, with Dec 2024 value amounting to $1.9 million.

  • Dianthus Therapeutics' Non-Current Deffered Revenue rose 848.12% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year increase of 848.12%. This contributed to the annual value of $1.9 million for FY2024, which is 159.24% up from last year.
  • Dianthus Therapeutics' Non-Current Deffered Revenue amounted to $1.9 million in FY2024, which was up 159.24% from $736,000 recorded in FY2023.
  • Dianthus Therapeutics' 5-year Non-Current Deffered Revenue high stood at $1.9 million for FY2024, and its period low was $736,000 during FY2023.
  • In the last 3 years, Dianthus Therapeutics' Non-Current Deffered Revenue had a median value of $791,000 in 2022 and averaged $1.1 million.
  • In the last 5 years, Dianthus Therapeutics' Non-Current Deffered Revenue fell by 6.95% in 2023 and then soared by 159.24% in 2024.
  • Yearly analysis of 3 years shows Dianthus Therapeutics' Non-Current Deffered Revenue stood at $791,000 in 2022, then declined by 6.95% to $736,000 in 2023, then surged by 159.24% to $1.9 million in 2024.